RESEARCH ARTICLE

Differences in Gene-Gene Interactions in Graves’ Disease Patients Stratified by Age of Onset

Beata Jurecka-Lubieniecka1*, Tomasz Bednarczuk2, Rafal Ploski3, Jolanta Krajewska1, Dorota Kula1, Malgorzata Kowalska1, Andrzej Tukiendorf4, Zofia Kolosza4, Barbara Jarzab1

1 Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, 2 Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland, 3 Department of Medical Genetics, Forensic Medicine, Medical University of Warsaw, Warsaw, Poland, 4 Department of Epidemiology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

* blubieniecka@gmail.com

Abstract

Background
Graves’ disease (GD) is a complex disease in which genetic predisposition is modified by environmental factors. Each gene exerts limited effects on the development of autoimmune disease (OR = 1.2–1.5). An epidemiological study revealed that nearly 70% of the risk of developing inherited autoimmune thyroid diseases (AITD) is the result of gene interactions. In the present study, we analyzed the effects of the interactions of multiple loci on the genetic predisposition to GD. The aim of our analyses was to identify pairs of genes that exhibit a multiplicative interaction effect.

Material and Methods
A total of 709 patients with GD were included in the study. The patients were stratified into more homogeneous groups depending on the age at time of GD onset: younger patients less than 30 years of age and older patients greater than 30 years of age. Association analyses were performed for genes that influence the development of GD: HLADRB1, PTPN22, CTLA4 and TSHR. The interactions among polymorphisms were analyzed using the multiple logistic regression and multifactor dimensionality reduction (MDR) methods.

Results
GD patients stratified by the age of onset differed in the allele frequencies of the HLADRB1*03 and 1858T polymorphisms of the PTPN22 gene (OR = 1.7, p = 0.003; OR = 1.49, p = 0.01, respectively). We evaluated the genetic interactions of four SNPs in a pairwise fashion with regard to disease risk. The coexistence of HLADRB1 with CTLA4 or HLADRB1 with PTPN22 exhibited interactions on more than additive levels (OR = 3.64, p = 0.002; OR = 4.20, p < 0.001, respectively). These results suggest that interactions between
these pairs of genes contribute to the development of GD. MDR analysis confirmed these interactions.

**Conclusion**

In contrast to a single gene effect, we observed that interactions between the *HLADRB1/PTPN22* and *HLADRB1/CTLA4* genes more closely predicted the risk of GD onset in young patients.

**Introduction**

Autoimmune thyroid diseases (AITDs) are multifactorial diseases involving both susceptibility alleles of a number of genes and environmental factors [1,2]. Causal therapy by eliminating autoantigens is not available for the treatment of AITDs [3]. Therefore, the elucidation of the genetic factors that are involved in the pathogenesis of AITDs is critical for early diagnosis and effective treatment [4,5].

Because multiple genes may be involved in the development of GD, investigations of the interactions of multiple genes are essential to understanding the genetic mechanisms underlying this complex disease [6]. Single gene polymorphisms identified in the entire GD population exhibit only a limited effect on the development of autoimmune diseases (OR = 1.2–1.5) [7]. An epidemiological study revealed that nearly 70% of the risk of developing inherited AITD is the result of the interaction of multiple genes [8]. Genetic interactions have been reported in other diseases with immunological backgrounds, such as allergic asthma or rheumatoid arthritis [9,10]. However, in GD, the gene interactions that significantly influence disease development are unknown. The complex interactions among genes and environmental factors complicates the identification of polymorphisms of susceptible genes involved in the development of GD. Young patients are susceptible to environmental factors for a shorter time than older patients, potentially simplifying the identification of a genetic predisposition for the development of complex diseases such as AITDs [11]. Recent studies of the human genome have confirmed the hypothesis that the contribution of genetic predisposition to complex diseases, such as GD, is stronger in young patients. Thus, the age at time of onset is considered one of the most important parameters of a disease phenotype [11]. An association between genetic markers and age at time of onset has been reported in patients with type 1 diabetes, rheumatoid arthritis and multiple sclerosis [12–14].

In the present study, we examined the interactions among genes associated with GD in the Polish population for the first time [15–21]. The patients were divided into two subgroups according to the age criterion of onset (30 years of age at onset of GD), similar to the analyses performed in the whole-genome study.

Our study reveals distinctive features of the genetic predisposition to GD in young patients that include both the participation of single polymorphisms and, in particular, their interactions.

**Materials and Methods**

**Subjects**

This study consisted of 709 Polish patients who were diagnosed with GD. Patients were recruited between 2003 and 2011 from the Department of Nuclear Medicine and Endocrine Oncology, Center of Oncology, Gliwice, and the Department of Endocrinology, Medical University of Warsaw.
The patients with GD were divided into the following two groups based on age at time of onset of GD: a young patient group with GD onset at ≤ 30 years of age (N = 168); and the older patient group with GD onset at > 30 years of age (N = 541). All patients were of Caucasian origin (S1 Table). The clinical characteristics of the patients are summarized in Table 1. The diagnosis of GD was based on clinical manifestations of hyperthyroidism and at least one of two phenotypes: Graves’ ophthalmopathy or laboratory detection of TSHR autoantibodies (Brahms, Berlin, Germany). The study received approval from the ethics committees of the Medical Research Centre, Polish Academy of Science, and the Maria Sklodowska-Curie Memorial Cancer Centre Institute of Oncology, Gliwice Branch. All GD patients in the investigated cohorts provided informed written consent to participate in the present study.

Methods

Genomic DNA from all participants was extracted from peripheral blood leukocytes using a routine salting-out method. HLA
db1 genotyping was performed using sequence-specific oligonucleotides (SSOs, Innolipa HLA
db1, Innogenetics, Gent, Belgium) and sequence-specific primers (MSSP Class II DRB Only, One Lambda, Dynal All Set SSP DR test, Dynal Biotech, Oslo, Norway) in the Gliwice study, and with a Dynal All Set SSP Dr test (Dynal Biotech, Bromborough, Wirral, UK) in the Warsaw study. The CTLA4 and PTPN22 polymorphisms were analyzed using PCF-RFLP methods. In the Gliwice study, PCR was performed using 0.5 units of Hot Star Taq polymerase (Qiagen, Limburg, Germany). PCR products were visualized in 2% agarose gels stained with ethidium bromide and digested with the appropriate restriction enzymes for 3 h at 37°C. The digested DNA segments were then separated in 3% agarose gels. The identification of the rs179247 and rs12101255 polymorphisms in the TSHR gene was performed using the TaqMan SNP genotyping Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions.

Statistical Analyses

Case-control comparisons of the polymorphisms in different alleles and combinations of the polymorphisms were conducted to estimate the relative risk of developing GD in the two age groups based on odds ratios (with 95% confidence intervals) and the Bonferroni adjustment. The interactions between genes were analyzed based on the multifactor dimensionality reduction (MDR) method, which enabled the detection and characterization of the combined effects of multiple genes in the development of GD in the different age groups. The best model of combined polymorphisms of different loci was selected using tenfold cross-validations and maximum testing accuracy. ORs were calculated using the R package (http://cran.r-project.org). The MDR analysis was performed using MDR software (http://sourceforge.net/projects/mdr/).

Table 1. General clinical characteristics of patients with GD included in this study.

|                                | N = 709 |
|--------------------------------|---------|
| Gender: female: male; n (%)    | 562 (79.3): 147 (20.7) |
| Age of onset in years: valid N; mean ± SD | 709; 41.3 ± 14.27 |
| Patients with age of onset ≤ 30 years; valid N; mean age | 168; 21.7 ± 6.05 |
| Patients with age of onset > 30 years; valid N; mean age | 541; 47.2 ± 10.8 |
| Tobacco smokers: age of onset ≤ 30 years; valid N; n (%) | 53 (31.5) |
| Tobacco smokers: age of onset > 30 years; valid N; n (%) | 253 (46.8) |

doi:10.1371/journal.pone.0150307.t001

The patients with GD were divided into the following two groups based on age at time of onset of GD: a young patient group with GD onset at ≤ 30 years of age (N = 168); and the older patient group with GD onset at > 30 years of age (N = 541). All patients were of Caucasian origin (S1 Table). The clinical characteristics of the patients are summarized in Table 1. The diagnosis of GD was based on clinical manifestations of hyperthyroidism and at least one of two phenotypes: Graves’ ophthalmopathy or laboratory detection of TSHR autoantibodies (Brahms, Berlin, Germany). The study received approval from the ethics committees of the Medical Research Centre, Polish Academy of Science, and the Maria Sklodowska-Curie Memorial Cancer Centre Institute of Oncology, Gliwice Branch. All GD patients in the investigated cohorts provided informed written consent to participate in the present study.
Results

The patients were divided into two groups (a young patient group and an older patient group) according to age at GD onset. To evaluate the genetic interactions in a pairwise fashion, a re-analysis of the allele frequency and genotype distribution of the analyzed polymorphisms was conducted. The allele frequencies of HLADRB1*03 in the HLADRB1 locus, 1858T in the PTPN22 locus, 49G in the CTLA4 locus, and rs179247 in the TSHR locus were characterized. The rs12101255 polymorphism of the TSRS gene was not analyzed because of a strong linkage disequilibrium between rs179247 and rs12101255 (D’ = 0.99). We evaluated the interactions between these polymorphisms. To minimize the influence of known environmental factors, separate analyses of non-smokers of different ages at time of GD onset were conducted. All four SNPs examined were in Hardy-Weinberg equilibrium.

Allele frequencies and genotypes distribution

The allele frequencies of the HLADRB1*03 and 1858T polymorphisms of the PTPN22 gene differed in GD patients stratified by the age of onset. The frequencies of the HLADRB1*03 allele and 858T allele were significantly higher in the younger patients than in the older patients (30.7% vs. 20.7%, OR = 1.70, p = 0.0031; 22.7% vs. 16.5%, OR = 1.49, p = 0.0187, respectively) (Table 2).

Significant differences in the distribution of genotypes were also observed; the frequencies of carriers of the HLADRB1*03 allele and those homozygous for the 1858T allele were significantly higher in younger patients (age-of-onset ≤30 years) than in the older patients (Table 2).

Similar results were obtained for the non-smoking young patients. The frequency of the HLADRB1*03 allele was significantly higher in the young non-smoking patients (N = 65) than in the older non-smoking patients (N = 150) (30.8% vs. 21%, OR = 1.67, p = 0.0293). A higher proportion of young non-smoking patients were carriers of the HLADRB1*03 allele compared to the older non-smoking patients (58.1% vs. 40%, OR = 2.11, p = 0.0128).

The frequency of the 1858T allele of the PTPN22 gene was significantly higher in the young non-smoking patients (N = 48) than in the older non-smoking patients (N = 58) (25.5% vs. 15.8%, OR = 1.83, p = 0.0055). The genotypes of the 1858T allele were significantly more diverse in the young non-smoking patients compared to the older non-smoking patients (42.5% vs. 28.8%, OR = 1.83, p = 0.0218).

No significant differences in the frequencies of the 49G polymorphism of the CTLA4 gene or the rs179247 polymorphism of the TSHR gene were identified between the two age groups. However, a tendency toward a higher frequency of rare alleles of both genes was identified in the young patients compared to the older patients (Table 2).

The risk of GD development in young patients compared to older patients was analyzed by logistic regression. The analysis was performed after adjusting for smoking status, a common environmental risk factor in GD development. Polymorphisms of the PTPN2 and HLADRB3 genes were assessed because the genotype distributions of these polymorphisms differed significantly in young and older patients. Young carriers of minor alleles of both HLADRB1*03 and 1858T in PTPN22 polymorphisms exhibited a significantly higher odd ratio (OR) compared to the older carriers (OR = 2.38, p = 0.001, OR = 1.81, p = 0.018, respectively) (Table 3). The results of the logistic regression are consistent with the genotype distribution analyses.

Gene-gene interactions effects

The associations of the two-SNP combinations were statistically evaluated by multiple logistic regression. Among the patients with different ages at time of onset, we assessed the differences in the frequencies of the polymorphism pairs of CTLA4/HLADRB1, CTLA4/TSHR, CTLA4/
PTPN22, HLA DRB1/TSHR, HLA DRB1/PTPN22 and TSHR/PTPN22. The OR values were estimated compared to the double wild-type genotype.

Significant differences in the frequencies of the HLADRB/CTLA4, HLADRB1/TSHR, HLADRB1/PTPN22, and PTPN22/TSHR pairs of polymorphisms were observed between young and older patients. These pairs of polymorphisms were more prevalent in younger-age-

| Gene          | Patients (N) | Allele/ genotypes | ≤30GD,N (% ) | >30GD,N (% ) | OR (95% CI) | ≤30GD vs. >30D | p* value |
|---------------|--------------|--------------------|--------------|--------------|-------------|----------------|----------|
| PTPN22        | 143          | C                  | 221 (77.3)   | 683 (83.5)   | 1.0 (ref.)  |                |          |
|               |              | T                  | 65 (22.7)    | 135 (16.5)   | 1.49 (1.07–2.07) | 0.0748       |
|               |              | Genotypes         | CC           | 88 (61.5)    | 281 (68.7)  | 1.0 (ref.)   |          |
|               |              | CT                 | 45 (31.5)    | 121 (29.6)   | 1.19 (0.78–1.80) | 1.00    |
|               |              | TT                 | 10 (7.0)     | 7 (1.7)      | 4.56 (1.69–12.34) | 0.0048      |
|               |              | Carriers           | CT+TT        | 55 (38.5)    | 128 (31.3)  | 1.37 (0.92–2.04) | 0.4720    |
| CTLA4         | 141          | A                  | 134 (47.5)   | 487 (50.7)   | 1.0 (ref.)  |                |          |
|               |              | G                  | 148 (52.5)   | 473 (49.3)   | 1.14 (0.87–1.48) | 1.00    |
|               |              | Genotypes         | AA           | 36 (25.5)    | 123 (25.6)  | 1.0 (ref.)   |          |
|               |              | AG                 | 62 (44.0)    | 241 (50.2)   | 0.88 (0.55–1.40) | 1.00    |
|               |              | GG                 | 43 (30.5)    | 116 (24.2)   | 1.27 (0.76–2.11) | 1.00    |
|               |              | Carriers           | GG+AG        | 105 (74.5)   | 357 (74.4)  | 1.00 (0.65–1.55) | 1.00    |
| HLA DRB1      | 101          | DR3-               | 140 (69.3)   | 511 (79.3)   | 1.0 (ref.)  |                |          |
|               |              | DR3+               | 62 (30.7)    | 133 (20.7)   | 1.70 (1.19–2.43) | 0.0124   |
|               |              | Genotypes         | DR3-/-       | 42 (41.6)    | 196 (60.9)  | 1.0 (ref.)   |          |
|               |              | DR3+/-             | 56 (55.4)    | 119 (37.0)   | 2.20 (1.39–3.48) | 0.0028   |
|               |              | DR3+/+             | 3 (3.0)      | 7 (2.2)      | 2.00 (0.50–8.05) | 1.00    |
|               |              | Carriers           | DR3 -/+ or DR3+/+ | 59 (58.4) | 126 (39.1)  | 2.19 (1.39–3.44) | 0.0028   |
| TSHR          | 136          | A                  | 121 (44.5)   | 383 (49.6)   | 1.0 (ref.)  |                |          |
|               |              | G                  | 151 (55.5)   | 389 (50.4)   | 1.23 (0.93–1.62) | 0.5828   |
|               |              | Genotypes         | GG           | 28 (20.6)    | 110 (28.5)  | 1.0 (ref.)   |          |
|               |              | AG                 | 65 (47.8)    | 163 (42.2)   | 1.57 (0.95–2.60) | 0.3240   |
|               |              | AA                 | 43 (31.6)    | 113 (29.3)   | 1.49 (0.87–2.57) | 0.5880   |
|               |              | Carriers           | AA+AG        | 108 (79.4)   | 276 (71.5)  | 1.54 (0.96–2.46) | 0.2880   |

*with Bonferroni corrections; GD: Graves’ disease; ≤30 GD: patients with age of onset of GD ≤30 years; >30 GD: patients with age of onset of GD >30 years; OR: odds ratio; 95% CI: 95% confidence interval; OR = 1.0 (ref.): referent category indicating the level of references; Carriers: carriers of minor alleles

doi:10.1371/journal.pone.0150307.t002

### Table 3. Odds ratio analysis of young patients compared to older patients with adjustment for smoking.

| Gene          | Young/older | OR(95% CI) | P       |
|---------------|-------------|------------|---------|
| PTPN22        | CC          | 84/260     | 1 (ref.) |
|               | CT+TT (carriers) | 54/121   | 1.81 (1.11–2.97) | 0.018    |
| HLA DRB1      | DR3 -/-     | 40/181     | 1 (ref.) |
|               | DR3 +/- or DR3+/+ (carriers) | 59/120 | 2.38 (1.47–3.84) | 0.001    |

doi:10.1371/journal.pone.0150307.t003
of-onset (≤30) patients than in older patients (41.6% vs. 29.2%; 45.4% vs. 26%; 24.2% vs. 9%; and 32.6% vs. 21.8%, for young patients vs. older patients, respectively).

In young patients, the PTPN22 polymorphism 1858T, CTLA4 polymorphism 49G, or TSHR polymorphism rs179247 were significantly associated with the disease in a HLADRB1*03 carrier background (OR = 4.2, p = 0.001, OR = 3.64, p = 0.0023, OR = 2.17, p = 0.036, respectively) (Table 4). The coexistence of HLADRB1 with CTLA4 and HLADRB1 with PTPN22 significantly increased the odds ratio compared to additive effects, suggesting that the interactions between these two genes are involved in the development of GD (OR = 3.64, p = 0.0023 vs. 1.0 × 2.19 = 2.19; OR = 4.20, p = 0.0001 vs. 2.19 × 1.37 = 3.00, respectively) (Table 4). The odds ratio analysis for minor allele carriers was considered in the interaction assessment.

Pairs of other genes, such as CTLA4/TSHR and CTLA4/PTPN22, were more frequent in the young patients, resulting in a higher odds ratio in this group. However, this relationship was not statistically significant.

We re-confirmed interactive genetic effects by MDR analysis to test the 2-way gene-gene interaction model. The MDR method identified 3 pairs of genes, HLADRB3/PTPN22, HLADRB3/CTLA4, and HLADRB3/TSHR, that significantly differentiated young patients from older patients (Fig 1). The SNP HLADRB1*03 had the highest balanced accuracy and cross-validation consistency among the four SNPs, whereas 1858T PTPN22 and HLADRB1*03 had the highest balanced accuracy and best cross-validation consistency among the pairwise interactions (Table 5). HLADRB3 and PTPN22 homozygosity for the wild allele were more frequent in older patients, whereas rare allele carriers were more frequent in younger patients.

Table 4. Differences between the risk of GD onset in young patients compared to older patients according to the coexistence of pairs of polymorphisms. OR: odds ratio; OR = 1.0 (ref.): referent category.

| Gene  | Genotype | OR (wild type) | p-value | OR (carriers) | p-value |
|-------|----------|----------------|---------|---------------|---------|
| HLA DR3 | | | | | |
| DRB3/- | AA (wild type) | 1.0 (ref.) | | | |
| | DRB3 -/+ and +/+ (carriers) | OR = 4.33 p = 0.003 * | | | |
| CTLA4 | AA (wild type) | 1.0 (ref.) | | | |
| | GG + AG (carriers) | OR = 2.05 p = 0.105 | | OR = 3.64 p = 0.0023 * | |
| PTPN22 | CC (wild type) | 1.0 (ref.) | | OR = 1.78 p = 0.051 * | |
| | TT + CT (carriers) | OR = 1.18 p = 0.643 | | OR = 4.2 p = 0.0001 * | |
| TSHR | GG (wild type) | 1.0 (ref.) | | OR = 1.14 p = 0.771 | |
| | AA + AG (carriers) | OR = 0.83 p = 0.622 | | OR = 2.17 p = 0.036 * | |

* Statistical significance; carriers: carriers of minor alleles

Fig 1. Results of the MDR analysis of the gene pair models differentiating the patient subgroups according to age at time of GD onset.

doi:10.1371/journal.pone.0150307.g001
Discussion

In our study, an association between gene interactions and the risk of GD was identified for the first time in the Polish population using two rounds of analysis. First, subset analysis was conducted to obtain more homogenous research groups. Second, the gene interactions were analyzed using appropriate tests. Complex diseases are heterogeneous; many genes interact with environmental factors and affect the development of disease [22–24]. Heterogeneity hampers the identification of gene polymorphisms that considerably increase the risk of morbidity [25].

Separation of a more homogeneous group of patients according to age at the time of GD onset, including younger-age-of-onset (≤30) patients and older patients, is a simple analytical approach that partially eliminates the limitations associated with the heterogeneity of the analyzed group and shortens the time of the influence of environmental factors.

Our assessment of genetic predisposition to GD in young patients based on the analysis of subgroups of different ages at onset revealed differences in the incidences of the analyzed polymorphisms. At the level of allele frequencies, we identified a relationship between alleles \textit{HLADRB1}^*03 and 1858T in the gene \textit{PTPN22} and young age at time of onset. Young carriers of \textit{HLADRB1}^*03 or homozygotes of allele 1858T are more likely to develop GD, despite shorter exposure to environmental factors. The results of the logistic regression are consistent with the genotype distribution analyses. Other polymorphisms, including \textit{CTLA4} and \textit{TSHR}, were more prevalent in younger age-of-onset (≤30) patients, but this difference was not significant. The major limitation of this study is the small numbers of patients in both groups, which may complicate the interpretation of negative results.

In the present study we focused on identifying interactions among multiple loci. We performed logistic regression analysis combined with the MDR method to assess gene-gene interactions in the development of GD. The MDR method, which overcomes several limitations of logistic regression, has been widely used for gene-gene interaction analyses [26,27].

The pairs of polymorphisms \textit{HLADRB1}^*03/49G \textit{CTLA4}, \textit{HLADRB1}^*03/rs179247 \textit{TSHR} and \textit{HLADRB1}^*03/1858T \textit{PTPN22} were closely associated with GD in young patients than in older patients. Patients with a combination of two risk genotypes have an increased risk for GD compared to patients with a single risk genotype. The increase in the odds ratio suggests an interaction of polymorphisms. The \textit{HLADRB1}^*03 and 1858T\textit{PTPN22} polymorphisms exhibited an association with GD, both independently and in interactions. Although, the 49G \textit{CTLA4} and rs179247\textit{TSHR} polymorphisms alone did not have significant effects, these polymorphisms do significantly increase disease risk in interactions with other genes.

In the young carriers of the aforementioned genotypes, the risk of GD is higher than that in the elderly patients. The MDR analysis identified the same pairs of polymorphisms.

SNP-based association analyses have become one of the most important approaches for interpreting the underlying molecular mechanisms of complex diseases. We focused on the specific role of polymorphism \textit{HLADRB1}^*03, which was present in every pair of analyzed polymorphisms [28,29]. The molecular mechanisms underlying gene interactions may correspond with the dominant role of \textit{HLADRB1}^*03 in the induction of autoimmune reactions and influence other polymorphisms in the propagation of immune reactions. Subunit A \textit{TSHR} altered by the intron polymorphism rs179247 is more effectively presented to lymphocytes T by

| Table 5. Summary of the MDR results. |
|--------------------------------------|
| Best model          | Training balanced accuracy | Testing balanced accuracy | Cross-validation consistency |
| HLADRB1              | 0.594                        | 0.5835                    | 10/10                     |
| PTPN22 –HLADRB1      | 0.6125                       | 0.5839                    | 9/10                      |

doi:10.1371/journal.pone.0150307.t005
antigen MHC class II \textit{HLA}DRB1*03 \cite{30,31}. The full activation of immune reactions may be propagated because T lymphocyte activation is not hindered due to modifications in the protein molecule products of polymorphism 49G in the \textit{CTLA4} gene and in protein LYP due to the polymorphism 1858T in the \textit{PTPN22} gene \cite{32,33}.

Recent studies have reported only an association between young age at GD onset and single gene polymorphisms. Our previous study of 422 patients confirmed analyses reported by Lavard and Farid \cite{16,34,35}. These studies suggested an association of \textit{HLA}DRB1*03 and young age at time of GD onset in the Caucasian population. Other alleles of \textit{HLA}DRB1 were identified in young Chinese and Japanese populations \cite{36,37}. In turn, studies by Skorka demonstrated a correlation of 1858T in gene \textit{PTPN22} with young age at time of GD onset \cite{15}.

Interactions between genes \textit{HLA} DRB1, \textit{CTLA4}, \textit{PTPN22} and \textit{TSHR} in the development of GD were not observed in non-age-differentiated groups of GD patients. Based on genetic profiling, Yin et al. did not identify any associations of \textit{HLA}DRB1 with \textit{CTLA4} 49G, \textit{TSHR} rs2268458, \textit{IL23R} rs10889677 or rs2201841. Those analyses were conducted in patients without GO in whom GD was diagnosed at an average age of 51 years \cite{38}. Assessing the influence of \textit{HLA} DRB1*03 with \textit{CTLA4} did not reveal independent effects \cite{39,40}. In the age-differentiated groups of patients with GD, the relationship between \textit{PTPN22} and the age at time of GD onset was analyzed. Unfortunately, the gene interaction analysis was conducted for the entire group, and the age at time of onset was not provided. Allele 1858 T of gene \textit{PTPN22}, \textit{HLA} DRB1*03 and allele 49G of gene \textit{CTLA4} were identified as independent contributors to the pathogenesis of GD, without significant interactions \cite{15}. We obtained similar results in the present study when comparing the entire group and old patients. The lack of an increase in ORs for coexisting polymorphisms in relation compared to single polymorphisms indicates the independent participation of these polymorphisms in GD pathogenesis in older patients. However, gene interaction effects in the entire group are unclear due to the heterogeneity of this group.

Identifying patient genotypes, including specific pairs of genes, may facilitate early prophylaxis. Additionally, because costimulatory signals are critical for immunological reactions, these molecules may be therapeutic targets for the efficient treatment of patients with GD.

Despite the demonstration of the role of gene-gene interactions in GD development, certain research limitations should be considered. A limitation of this study is the sample size; the separation of groups of patients with specific pairs of polymorphisms decreases the size of these subgroups. Additionally, we could not completely exclude the influence of environmental risks.

To summarize, our study demonstrates that the genetic profiles of young patients with GD differ from those of older patients both in the occurrence of single locus genes and, in particular, the interaction of multiple loci. The gene-gene interactions more closely reflect GD risk than single polymorphisms. The interactions between the \textit{HLA}DRB1/PTPN22 and \textit{HLA}DRB1/\textit{CTLA4} genes significantly increase the likelihood of GD onset only in young patients.

**Supporting Information**

\textit{S1 Table. GD-patients: age of onset, smoking status, genes.} (DOCX)

**Author Contributions**

Conceived and designed the experiments: BJL BJ. Performed the experiments: BJL RP TB JK. Analyzed the data: BJL AT ZK. Contributed reagents/materials/analysis tools: DK MK. Wrote the paper: BJL AT.
References

1. Simmonds MJ, Gough SCL. Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin Exp Immunol. 2004; 136: 1–10. PMID: 15030506

2. Prummel M, Strieder T, Wiersinga W. The environment and autoimmune thyroid diseases. Eur J Endocrinol. 2004; 150: 605–618. PMID: 15132715

3. Rioux JD, Abbas AK. Paths to understanding the genetic basis of autoimmune disease. Nature. 2005; 435: 584–589. PMID: 15931210

4. Ploski R, Szymanski K, Bednarczuk T. The genetic basis of Graves' disease. Curr Genomics. 2011; 12: 542–563. doi: 10.2174/138920211798120772 PMID: 22654555

5. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' orbitopathy. Thyroid. 2002; 12: 855–860. PMID: 12487767

6. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered. 2003; 56: 73–82. PMID: 14614241

7. Zeitlin AA, Simmonds MJ, Gough SCL. Genetic developments in autoimmune thyroid disease: an evolutionary process. Clin Endocrinol. 2008; 68: 671–682.

8. Brix TH, Kyvik KO, Christensen K, Hegedüs L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001; 86: 930–934. PMID: 1159480

9. Lee SH, Lee EB, Shin ES, Lee JE, Cho S, Min KU, Park HW. The interaction between allelic variants of CD86 and CD40LG: a common risk factor of allergic asthma and rheumatoid arthritis. Allergy Asthma Immunol Res. 2014; 6: 137–141. doi: 10.4168/aair.2014.6.2.137 PMID: 24587950

10. Su MW, Tung KY, Liang PH, Tsai CH, Kuo NW, Lee YL. Gene-gene and gene-environmental interactions of childhood asthma: a multifactor dimension reduction approach. PLoS One. 2012; 7: e30694. doi: 10.1371/journal.pone.0030694 PMID: 22355322

11. Tomer Y, Menconi F, Davies TF, Barbesino G, Rocchi R, Pinchera A, et al. Dissecting genetic heterogeneity in autoimmune thyroid diseases by subset analysis. J Autoimmun. 2007; 29: 69–77. PMID: 17644307

12. Paterson AD, Kennedy JL, Petronis A. Evidence for genetic anticipation in non-Mendelian diseases. Am J Hum Genet. 1996; 59: 264–268. PMID: 8659536

13. Radstake TR, Barrera P, Albers MJ, Swinkels HL, van de Putte LB, van Riel PL, et al. Genetic anticipation in rheumatoid arthritis in Europe. European Consortium on Rheumatoid Arthritis Families. J Rheumatol. 2001; 28: 962–967. PMID: 11361223

14. Cocco E, Sardu C, Lai M, Spinicci G, Contu P, Marrosu MG. Anticipation of age at onset in multiple sclerosis: a Sardinian cohort study. Neurology. 2004; 62: 1794–1798. PMID: 15159480

15. Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol. 2005; 62: 679–682.

16. Jurecka-Lubieniecka B, Ploski R, Kula D, Krol A, Bednarczuk T, Kolasza Z, et al. Association between age at diagnosis of Graves' disease and variants in genes involved in immune response. PLoS One. 2013; 8: e59349. doi: 10.1371/journal.pone.0059349 PMID: 23544060

17. Jurecka-Lubieniecka B, Ploski R, Kula D, Szymanski K, Bednarczuk T, Ambroziak U, et al. Association between polymorphisms in the TSHR gene and Graves' orbitopathy. PLoS One. 2014; 9: e102653. doi: 10.1371/journal.pone.0102653 PMID: 25061884

18. Kula D, Bednarczuk T, Jurecka-Lubieniecka B, Polanska J, Hasse-Lazar K, Jarzab M, et al. Interaction of HLADR1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1*07. Thyroid. 2006; 16(5): 447–53. PMID: 16756466

19. Bednarczuk T, Hiromatsu Y, Seki N, Ploski R, Fukutani T, Kurylowicz A, et al. Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. Hum Immunol. 2004; 65: 632–639. PMID: 15219383

20. Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M, et al. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur J Endocrinol. 2003; 148: 13–18. PMID: 12534352

21. Ploski R, Brand OJ, Jurecka-Lubieniecka B, Franaszczuk M, Kula D, Krajewski P, et al. Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One. 2010; 5: e15512. doi: 10.1371/journal.pone.0015512 PMID: 21124799

22. Moore JH. A global view of epistasis. Nat Genet. 2005; 37: 13–14. PMID: 15624016
23. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet. 2004; 20: 640–647. PMID: 15522460
24. Davies TF. Really significant genes for autoimmune thyroid disease do not exist – so how can we predict disease? Thyroid. 2007; 17: 1027–1029. PMID: 18047427
25. Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present and future. Thyroid. 2010; 20: 715–725. doi: 10.1089/thy.2010.1644 PMID: 20604685
26. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003; 19: 376–382. PMID: 12584123
27. Guo-Bo C, Yi X, Hai-Ming X, Ming DL, Jun Z, et al. Practical and theoretical considerations in study design for detecting gene-gene interactions using MDR and GMDR approaches. PLoS One. 2011; 6: e16981. doi: 10.1371/journal.pone.0016981 PMID: 21386969
28. Sawai Y, DeGroot J. Binding of human thyrotropin receptor peptides to a Graves’ disease-predisposing human leukocyte antigen class II molecule. J Clin Endocrinol Metab. 2000; 85: 1176–1179. PMID: 10720058
29. Ban Y, Davies TF, Greenberg DA, Concepcion ES, Osman R, Oashi T, et al. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves’ disease. Genes Immun. 2004; 5: 203–208. PMID: 15029234
30. Brand OJ, Gough SCL. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol. 2010; 322: 135–143. doi: 10.1016/j.mce.2010.01.013 PMID: 20083159
31. Davies TF, Yin X, Latif R. The genetics of the thyroid stimulating hormone receptor: history and relevance. Thyroid. 2010; 20: 727–735. doi: 10.1089/thy.2010.1636 PMID: 20578897
32. Chistiakov D, Turekulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol. 2003; 31: 21–36. PMID: 12914522
33. Heward JM, Brand OJ, Barrett JC, Carr-Smith JD, Franklyn JA, Gough SC. Association of PTPN22 haplotypes with Graves’ disease. J Clin Endocrinol Metab. 2007; 92: 685–690. PMID: 17148556
34. Lavard L, Madsen HO, Perrild H, Jacobsen BB, Svejgaard A. HLA class II associations in juvenile Graves’ disease: indication of a strong protective role of the DRB1*0701, DQA1*0201 haplotype. Tissue Antigens. 1997; 50: 639–641. PMID: 9458117
35. Farid NR, Stone E, Johnson G. Graves’ disease and HLA: clinical and epidemiologic association. Clin Endocrinol. 1980; 13: 535–544.
36. Wong GW, Cheng SH, Dorman JS. The HLA-DQ associations with Graves’ disease in Chinese children. Clin Endocrinol. 1999; 50: 493–495.
37. Onuma H, Ota M, Sugeno A, Inoko H. Association of HLA-DPB1*0501 with early-onset Graves’ disease in Japanese. Hum Immunol. 1994; 39: 195–201. PMID: 8026987
38. Yin X, Latif R, Bahn R, Davies TF. Genetic profiling in Graves’ disease: further evidence for lack of a distinct genetic contribution to Graves’ ophthalmopathy. Thyroid. 2012; 22: 730–736. doi: 10.1089/thy.2012.0007 PMID: 22663548
39. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF. The cytotoxic T lymphocyte antigen-4 is a major Graves’ disease locus. Hum Mol Genet. 1999; 8: 1195–1199. PMID: 10369864
40. Ban Y, Concepcion ES, Villanueva R, Greenberg DA, Davies TF, Tomer Y. Analysis of immune regulatory genes in familial and sporadic Graves’ disease. J Clin Endocrinol Metab. 2004; 89: 4562–4568. PMID: 15356063